Lumiracoxib (Novartis)
Ding, C and Jones, G (2002) Lumiracoxib (Novartis). IDrugs, 5 (12). pp. 1168-1172. ISSN 1369-7056 ![[img]](http://eprints.utas.edu.au/style/images/fileicons/application_pdf.png)  Preview |
| PDF - Requires a PDF viewer 95Kb |
Official URL: http://www.biomedcentral.com/1369-7056/5?issue=12 AbstractLumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001. | Item Type: | Article |
|---|
| ID Code: | 3523 |
|---|
| Deposited By: | Dr Changhai / C Ding |
|---|
| Deposited On: | 14 Mar 2008 11:23 |
|---|
| Last Modified: | 18 Jul 2008 20:41 |
|---|
| ePrint Statistics: | View statistics for this ePrint |
|---|
Repository Staff Only: item control page
|